Crescent Biopharma (CBIO) Retained Earnings (2013 - 2026)
Crescent Biopharma (CBIO) posted quarterly Retained Earnings of $379.2 million for Q2 2026, up 99.51% year-over-year from $190.0 million in Q2 2025, and up 1.13% quarter-over-quarter from $374.9 million in Q1 2026.
Crescent Biopharma (CBIO) Retained Earnings (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Retained Earnings for 14 consecutive years, with $379.2 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Retained Earnings rose 99.51% year-over-year to $379.2 million; the TTM figure through Jun 2026 stood at $379.2 million (up 99.51% YoY), while the FY2025 annual figure was $370.8 million, up 2175.3% from the prior year.
- Retained Earnings rose to $379.2 million in Q2 2026 per CBIO's latest filing, from $374.9 million in the prior quarter.
- Across five years, Retained Earnings topped out at $500.0 million in Q1 2025 and bottomed at -$17.9 million in Q4 2024.
- Historically, Retained Earnings has averaged $404.8 million across 5 years, with a median of $459.9 million in 2022.
- Annual changes were most pronounced in 2024 — Retained Earnings slumped 103.61% — and 2025, when it surged 2175.3%.
- Crescent Biopharma's Retained Earnings stood at $462.5 million in 2022, then advanced by 7.0% to $494.8 million in 2023, then plunged by 103.61% to -$17.9 million in 2024, then soared by 2175.3% to $370.8 million in 2025, then climbed by 2.26% to $379.2 million in 2026.
- Business Quant data shows CBIO's Retained Earnings at $379.2 million in Q2 2026, $374.9 million in Q1 2026, and $370.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.08 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.11 Bn | 78.11 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 56.09 Bn | 50.96 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.49 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 4.38 Bn |
| 10 | Crescent Biopharma | 1.07 Bn | 897.86 Mn | - | 379.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 379.16 Mn |
| Mar 31, 2026 | -195.09 Mn |
| Dec 31, 2025 | 370.79 Mn |
| Sep 30, 2025 | 192.04 Mn |
| Jun 30, 2025 | -54.81 Mn |
| Mar 31, 2025 | 500.02 Mn |
| Dec 31, 2024 | 2.39 Mn |
| Sep 30, 2024 | -487.14 Mn |
| Jun 30, 2024 | -477.32 Mn |
| Mar 31, 2024 | -467.22 Mn |
| Dec 31, 2023 | -456.49 Mn |
| Sep 30, 2023 | -447.40 Mn |
| Jun 30, 2023 | -438.20 Mn |
| Mar 31, 2023 | -429.90 Mn |
| Dec 31, 2022 | 462.46 Mn |
| Sep 30, 2022 | -409.34 Mn |
| Jun 30, 2022 | 456.49 Mn |
| Mar 31, 2022 | 455.53 Mn |
| Dec 31, 2021 | -372.90 Mn |
| Sep 30, 2021 | -355.48 Mn |